Pharma BD Deal Intelligence
A regulatory remedy purchase, not a strategic bet: Boehringer Ingelheim bought roughly half of Wyeth's Fort Dodge Animal Health business as an FTC-mandated divestiture from the Pfizer-Wyeth merger, at an undisclosed price. BI shuttered the original Fort Dodge plant within two years, though the acquired vaccine brands lived on and were eventually folded into an $885M sale to Elanco seven years later.
A regulatory remedy purchase, not a strategic bet — BI kept the vaccine brands ~7 years then folded them into a bigger $885M exit to Elanco as its own FTC price for buying Merial; the original Fort Dodge, Iowa plant was shuttered within 2 years.
Full analysis, sources & comparables →Pfizer announced on September 21, 2009 the divestiture covered "cattle and small animal vaccines," "animal health pharmaceuticals," "research and manufacturing…
The FTC consent order required Pfizer 'to sell approximately half of Wyeth's Fort Dodge U.S. animal health business to Boehringer Ingelheim Vetmedica, Inc.,…
Pfizer completed its acquisition of Wyeth on October 15, 2009 following approval from all required government authorities; FTC conditions required divestiture…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
FTC-mandated divestiture: ~half of Wyeth's Fort Dodge US animal health business (cattle/dog/cat vaccines, horse vaccines) divested as condition of Pfizer-Wyeth merger. Source: FTC, Pfizer press.
A regulatory remedy purchase, not a strategic bet — BI kept the vaccine brands ~7 years then folded them into a bigger $885M exit to Elanco as its own FTC price for buying Merial; the original Fort Dodge, Iowa plant was shuttered within 2 years.
Assessment window: 15yr post-close.
$68.0B Pfizer-Wyeth parent transaction $68B; Boehringer divestiture financial terms not disclosed
This is a regulatory-mandated animal-health divestiture rather than a single-indication deal. The transferred portfolio spanned cattle vaccines (respiratory and reproductive), companion-animal vaccines (canine/feline), equine vaccines and animal-health pharmaceuticals — categories where Pfizer's pre-existing animal-health unit and Wyeth's Fort Dodge had overlapping market positions, prompting FTC, Canadian, Australian, and EU competition authorities to require divestiture as a condition of the $68B Pfizer-Wyeth merger.
The 2009 Fort Dodge divestiture reshaped the global animal-health top-five. At the time of the deal, the major animal-health players were Pfizer Animal Health (post-Fort Dodge integration would become #1), Merial (Sanofi/Merck JV), Intervet/Schering-Plough (then merging with Merck), Bayer Animal Health, and Boehringer Ingelheim Vetmedica. The FTC consent order required Pfizer 'to sell approximately half of Wyeth's Fort Dodge U.S. animal health business to Boehringer Ingelheim Vetmedica, Inc., within 10 days of the acquisition,' covering 'vaccines for cattle, dogs, and cats, and other pharmaceutical products used in treating cattle, dogs, cats, and horses' (FTC, October 2009). Hubertus von Baumbach (then Boehringer Ingelheim board member, Finance & Animal Health) said: 'Fort Dodge Animal Health is a global industry leader recognized for its commitment to cutting-edge research and development with a product portfolio that is an excellent strategic fit with our existing product lines.' Chairman Andreas Barner emphasized strategic logic: 'The widening of our Animal Health business and our product portfolio is not a sales-driven decision, but rather is driven by the opportunity to add momentum to our strategy for organic growth' (The Cattle Site). The deal materially expanded Boehringer's vaccine franchise into a top-tier global animal-health competitor, setting up the consolidation cycle that culminated in the 2017 Boehringer-Sanofi swap (Boehringer's consumer health for Sanofi's Merial). (Forward-looking close: ten years post-close, Boehringer had become the world's #2 animal-health company after fully absorbing Merial in 2017, validating the Fort Dodge divestiture as a foundational scale acquisition; Pfizer's residual animal-health unit was spun off as Zoetis in 2013 and became the global #1.)
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim Vetmedica, Inc. / Wyeth/Fort Dodge Animal Health (divested assets) (this deal) | 2009 | — | 61 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| QIAGEN N.V. / DxS Ltd. | 2009 | $130M | 85 |
| Sigma-Tau Group / Enzon Pharmaceuticals (Specialty Pharma business) | 2009 | $327M | 85 |
← Browse all deals · How we score deals
More: 2009 deals